Clinical development failure
Pipeline value depends on demonstrating safety and efficacy in biomarker-defined cancers.
- Scope
- Darovasertib, ADC/DDR, MTAP, and next-generation programs
- Materiality
- high
IDEAYA Biosciences, Inc.
IDEAYA Biosciences is a clinical-stage precision oncology company focused on discovering and developing targeted cancer therapies matched to specific molecular alterations. Its pipeline centers on small-molecule programs, synthetic lethality, and antibody-drug conjugates, with development guided by companion diagnostics and biomarker selection.
−71,6 %
−52,0 %
+3 024,4 %
11.34
11.34
| % | |
|---|---|
| Darovasertib / uveal melanoma | 10% Clinical development of darovasertib for uveal melanoma, including combination and registrational studies. |
| ADC and DDR combinations | 25% Antibody-drug conjugate and DNA damage response combination programs in molecularly defined solid tumors. |
| MTAP pathway programs | 20% Targeted therapies aimed at MTAP-deleted cancers and related synthetic lethality biology. |
| Next-generation therapies | 20% Earlier-stage discovery and development programs beyond the current lead assets. |
| Collaboration revenue and diagnostics enablement | 25% Revenue from partnered R&D, licensing, milestones, and diagnostic-enabling activities. |
IDEAYA does not yet sell approved products; its current counterparties are pharmaceutical partners, diagnostic...
- Pharmaceutical collaboration partnersprimary
Partners such as GSK, Servier, Pfizer, Gilead, Biocytogen, and Hengrui support development, licensing, supply, or commercialization of specific programs.
- Diagnostic and biomarker partnersprimary
Companies like Foundation Medicine, Guardant Health, and Tempus help identify patients most likely to benefit from IDEAYA's therapies.
- Clinical investigators and trial sitesprimary
Academic and community oncology centers enroll patients into biomarker-selected studies and registrational trials.
- Future oncology prescriberssecondary
Specialist oncologists would prescribe approved products for defined cancer subtypes if the pipeline reaches commercialization.
- Contract manufacturing organizationssecondary
CMOs manufacture API, drug product, and related supply for preclinical, clinical, and future commercial use.
IDEAYA is headquartered in the United States and currently expects to commercialize any approved medicines first in the...
- •United States is the planned first commercial market
- •Europe is a potential expansion market for future products
- •Servier holds ex-U.S. rights to darovasertib worldwide
- •Clinical and diagnostic partners are globally distributed
- •Manufacturing is outsourced to third-party CMOs
IDEAYA's strategy is to build a precision oncology pipeline around molecularly defined cancers where biomarker...
01
Advance darovasertib in uveal melanomashort-term
This is the most advanced asset and a potential first commercial product.
02
Progress ADC, DDR, and MTAP pipeline programsmedium-term
Diversifies the pipeline and creates multiple shots on goal in precision oncology.
03
Expand biomarker and diagnostic capabilitiesmedium-term
Patient selection is central to the company's precision-medicine thesis and trial success.
04
Use partnerships for ex-U.S. commercialization and fundingshort-term
Partnerships reduce capital needs and provide external validation for programs.
IDEAYA is a clinical-stage biotech with no approved products, so its value depends on successful trials, regulatory...
Financing risk
The company has significant losses and will likely need additional capital to fund development.
- Scope
- Equity issuance, collaborations, or debt financing
- Materiality
- high
Competition from larger oncology companies
Rivals may develop similar targeted therapies faster or with greater resources.
- Scope
- Targeted oncology, synthetic lethality, and ADC markets
- Materiality
- high
Commercialization and reimbursement risk
Even approved products may face payer resistance or limited reimbursement in niche indications.
- Scope
- U.S. launch and future ex-U.S. markets
- Materiality
- medium
Manufacturing and supply-chain dependence
The company relies on third-party CMOs for API, drug product, and diagnostics supply.
- Scope
- Clinical and future commercial supply
- Materiality
- medium
Collaboration revenue recognition
Can cause large quarter-to-quarter swings in reported revenue
Contract assets and liabilities
Affects balance sheet presentation and revenue timing
Stock-based compensation
Impacts reported losses and non-cash expense trends
Marketable securities valuation
Fair value changes can affect other comprehensive income and liquidity disclosure
Black Diamond Therapeutics, Inc.
BDTX · Biological Products, (No Diagnostic Substances)
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Aldeyra Therapeutics, Inc.
ALDX · Pharmaceutical Preparations
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on discovering and developing therapies for immune-mediated diseases.
Erasca, Inc.
ERAS · Pharmaceutical Preparations
CASTLE BIOSCIENCES INC
CSTL · Services-Medical Laboratories
Castle Biosciences is a U.S.-based molecular diagnostics company that develops tissue-based tests to help clinicians make treatment and diagnosis decisions in…
EyePoint, Inc.
EYPT · Laboratory Analytical Instruments
: 28/04/2026